FIELD: medicine.
SUBSTANCE: the present innovation deals with carrying out a prevocational test, moreover, it is necessary to introduce pharmacological preparation into blood of a person under testing followed by detecting body reaction to its action, moreover, as the above-mentioned pharmacological preparation one should introduce reversible inhibitor of catecholamines α-methyl-p-tyrosine synthesis, then visually detect the presence/absence of tremor and/or muscular rigidity in a person under testing, at the presence of which it is possible to diagnose pathological process in its latent phase of flow. The innovation enables to establish the diagnosis long before the manifestation of clinical symptoms and enables to apply adequate methods of therapy due to using the so-called prevocational pharmacological test that helps to clinically illustrate functional insufficiency of nigrostriatal dopaminergic cerebral system being responsible for the regulation of motor behavior.
EFFECT: higher accuracy of diagnostics.
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION BASED ON ALPHA-METHYL-P-TYROSINE AND A METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2719575C1 |
METHOD FOR EARLY PRECLINICAL DIAGNOSTICS OF PARKINSON'S DISEASE BY CONCENTRATION OF CATECHOLAMINES IN PATIENT'S LACRIMAL FLUID | 2019 |
|
RU2775261C2 |
METHOD OF EARLY PRE-CLINICAL DIAGNOSIS OF PARKINSON'S DISEASE | 2015 |
|
RU2606591C1 |
METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2722666C1 |
METHOD OF OBTAINING POPULATION OF DOPAMINERGIC NEURONS FROM SUBSTANCE NIGRA OF MICE UNDER NORMAL AND PATHOLOGICAL CONDITIONS AND USE OF OBTAINED POPULATION FOR MOLECULAR BIOLOGICAL ANALYSIS | 2022 |
|
RU2811815C2 |
DIAGNOSTIC TECHNIQUE FOR PARKINSON DISEASE IN PATIENTS WITH OLFACTORY DYSFUNCTION | 2011 |
|
RU2478209C1 |
METHOD FOR DIAGNOSING NEURODEGENERATIVE PROCESS IN PARKINSON'S DISEASE | 2015 |
|
RU2581252C1 |
PHARMACEUTICAL COMPOSITION FOR RECOVERY FUNCTION OF SYMPATHETIC-ADRENAL SYSTEM, METHOD OF EVALUATION OF INDIVIDUAL EFFECTIVENESS OF THIS COMPOSITION FOR PATIENT THERAPY | 1999 |
|
RU2157196C1 |
DRUG PREPARATION FOR PARKINSON DISEASE | 2014 |
|
RU2545734C1 |
AGENT FOR TREATMENT AND PREVENTION OF PARKINSON'S DISEASE | 2006 |
|
RU2324492C1 |
Authors
Dates
2008-03-10—Published
2006-07-28—Filed